Dimensional Fund Advisors LP Lowers Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

Dimensional Fund Advisors LP lessened its holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) by 97.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,839 shares of the company’s stock after selling 241,897 shares during the period. Dimensional Fund Advisors LP’s holdings in Scholar Rock were worth $296,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Capital World Investors bought a new position in shares of Scholar Rock in the fourth quarter worth about $31,203,000. CANADA LIFE ASSURANCE Co lifted its position in shares of Scholar Rock by 347.1% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 16,888 shares of the company’s stock valued at $729,000 after buying an additional 13,111 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Scholar Rock by 1,283.7% during the fourth quarter. Marshall Wace LLP now owns 2,945,408 shares of the company’s stock valued at $127,301,000 after acquiring an additional 2,732,546 shares in the last quarter. EAM Investors LLC acquired a new position in shares of Scholar Rock during the fourth quarter valued at about $5,958,000. Finally, Jump Financial LLC acquired a new position in Scholar Rock in the 4th quarter worth approximately $3,246,000. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Trading Down 0.9%

Shares of NASDAQ:SRRK opened at $30.55 on Friday. The business’s 50 day moving average price is $31.19 and its 200-day moving average price is $35.91. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. The firm has a market capitalization of $2.90 billion, a price-to-earnings ratio of -13.00 and a beta of 0.37. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.04). On average, equities research analysts forecast that Scholar Rock Holding Co. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wedbush reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a research note on Wednesday. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $42.67.

Insider Transactions at Scholar Rock

In other Scholar Rock news, insider Tracey Sacco sold 5,000 shares of Scholar Rock stock in a transaction dated Friday, April 25th. The stock was sold at an average price of $32.83, for a total value of $164,150.00. Following the completion of the transaction, the insider now directly owns 71,750 shares of the company’s stock, valued at $2,355,552.50. The trade was a 6.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mo Qatanani sold 68,510 shares of Scholar Rock stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total value of $2,562,274.00. Following the completion of the transaction, the insider now directly owns 111,084 shares of the company’s stock, valued at approximately $4,154,541.60. This represents a 38.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 255,231 shares of company stock worth $9,220,236 in the last quarter. Company insiders own 13.30% of the company’s stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.